Literature DB >> 11378245

N(epsilon)(gamma-glutamyl)lysine in cerebrospinal fluid marks Alzheimer type and vascular dementia.

Z Nemes1, L Fésüs, A Egerházi, A Keszthelyi, I M Degrell.   

Abstract

N(epsilon)(gamma-glutamyl)lysine isodipeptide is released from the breakdown of proteins cross-linked by transglutaminase enzymes. Transglutaminase activation is a marker of apoptosis and elevated isodipeptide concentrations in body fluids might correlate with the intensity of apoptotic cell turnover. The concentration of N(epsilon)(gamma-glutamyl)lysine was measured in the cerebrospinal fluid (CSF) of patients with probable Alzheimer's disease (n = 14) and vascular type dementia (n = 11) and compared with not demented surgical controls (n = 17). Baseline levels of 26-62 nM/l (mean 37.9 +/- 8.7 SD) free isodipeptide were detected in control patients. CSF isodipeptide levels showed significant elevation in vascular (mean 95.6 +/- 45.1 SD) as well as Alzheimer patients (176.6 +/- 77.1 SD). Isodipeptide concentrations above 120 nM/l were 72% specific and 77% sensitive to Alzheimer's dementia, although the difference between the two dementias was statistically insignificant (p > 0.05). Determination of CSF N(epsilon)(gamma-glutamyl)lysine isodipeptide concentration offers a novel method for measurement of neurodegeneration in primary and mixed dementias.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378245     DOI: 10.1016/s0197-4580(01)00224-x

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  15 in total

1.  Effects of tissue transglutaminase on beta -amyloid1-42-induced apoptosis.

Authors:  Joseph J Wakshlag; Marc A Antonyak; Jason E Boehm; Karen Boehm; Richard A Cerione
Journal:  Protein J       Date:  2006-01       Impact factor: 2.371

Review 2.  Neurotoxicity in Alzheimer's disease: is covalently crosslinked A beta responsible?

Authors:  Ryan Naylor; Andrew F Hill; Kevin J Barnham
Journal:  Eur Biophys J       Date:  2007-12-07       Impact factor: 1.733

3.  Increased levels of gamma-glutamylamines in Huntington disease CSF.

Authors:  Thomas M Jeitner; Wayne R Matson; John E Folk; John P Blass; Arthur J L Cooper
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

4.  Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain.

Authors:  Soo-Youl Kim; Lyuben Marekov; Parvesh Bubber; Susan E Browne; Irina Stavrovskaya; Jongmin Lee; Peter M Steinert; John P Blass; M Flint Beal; Gary E Gibson; Arthur J L Cooper
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

Review 5.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

6.  Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria.

Authors:  Boris F Krasnikov; Soo-Youl Kim; Stephen J McConoughey; Hoon Ryu; Hui Xu; Irina Stavrovskaya; Siiri E Iismaa; Bryony M Mearns; Rajiv R Ratan; John P Blass; Gary E Gibson; Arthur J L Cooper
Journal:  Biochemistry       Date:  2005-05-31       Impact factor: 3.162

Review 7.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

8.  Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation.

Authors:  Dean M Hartley; Chaohui Zhao; Austin C Speier; Gavitt A Woodard; Shaomin Li; Zongli Li; Thomas Walz
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

Review 9.  Newly described clinical and immunopathological feature of dermatitis herpetiformis.

Authors:  Veronica Bonciolini; Diletta Bonciani; Alice Verdelli; Antonietta D'Errico; Emiliano Antiga; Paolo Fabbri; Marzia Caproni
Journal:  Clin Dev Immunol       Date:  2012-06-03

10.  Pilot proteomic analysis of cerebrospinal fluid in Alzheimer's disease.

Authors:  Justin McKetney; Daniel J Panyard; Sterling C Johnson; Cynthia M Carlsson; Corinne D Engelman; Joshua J Coon
Journal:  Proteomics Clin Appl       Date:  2021-04-26       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.